{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"CABOSUN II","nct_id":"NCT03541902","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cabosun-ii-nct03541902. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive cabozantinib PO QD on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.","label":"Group 1 (cabozantinib)","type":"EXPERIMENTAL"},{"description":"Participants receive sunitinib malate PO QD on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.","label":"Group 2 (sunitinib malate)","type":"EXPERIMENTAL"}],"collaborators":["Exelixis","National Cancer Institute (NCI)"],"completion_date":{"date":"2027-07-31","type":"ESTIMATED"},"conditions":["Malignant Neoplasms of Urinary Tract","Renal Cell Carcinoma","Chromophobe Renal Cell Carcinoma","Metastatic Renal Cell Carcinoma","Papillary Renal Cell Carcinoma","Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions","Sarcomatoid Renal Cell Carcinoma","Stage IV Renal Cell Cancer AJCC v8","Unclassified Renal Cell Carcinoma"],"enrollment":{"count":32,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Cabozantinib","otherNames":[],"type":"DRUG"},{"name":"Sunitinib Malate","otherNames":["SU011248","SU11248","sunitinib","Sutent"],"type":"DRUG"}],"last_update":"2026-07-16","lead_sponsor":"M.D. Anderson Cancer Center","official_title":"Cabosun Ii: Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-07-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) Evaluated Using RECIST 1.1 Criteria","timeFrame":"From randomization up to the time of disease progression or death up to two years"}],"references":[],"start_date":{"date":"2018-05-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT03541902"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cabosun-ii-nct03541902"}